NICE Turns Down Avastin For Yet Another Indication In Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s NICE issues draft guidance recommending against use of Avastin for first recurrence of platinum-sensitive advanced ovarian cancer, citing evidence and cost-effectiveness issues.